Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | July 24, 2026 | July 30, 2026 |
| Erasca, Inc.ERAS · Entity 3796 | President, R&D | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date July 24, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2036-07-23 | Direct | 118,000 |
Reported balance
After 2026-07-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 118,000 · Balance 118,000 F1: 1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Erasca, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.12 · Expires 2036-08-09 | Direct | 1,300,000 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 1,300,000 · Balance 1,300,000 F1: The reported option award was granted in connection with the Reporting Person's commencement of employment. Of the total option award, 21,480 shares were granted under the Issuer's 2021 Incentive Award Plan, with a portion intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code to the extent permitted by law. The remaining 1,278,520 shares were granted as a nonqualified stock option under the Issuer's 2026 Employment Inducement Incentive Award Plan. F2: The reported option award vests as follows: 25% of the shares subject to the option will vest on the first anniversary of the date of grant, and the remaining 75% of the shares will vest in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported option award was granted in connection with the Reporting Person's commencement of employment. Of the total option award, 21,480 shares were granted under the Issuer's 2021 Incentive Award Plan, with a portion intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code to the extent permitted by law. The remaining 1,278,520 shares were granted as a nonqualified stock option under the Issuer's 2026 Employment Inducement Incentive Award Plan.
F2: The reported option award vests as follows: 25% of the shares subject to the option will vest on the first anniversary of the date of grant, and the remaining 75% of the shares will vest in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:22 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 1,300,000 | $0.00 Strike: $18.12 | $0.00 |
DisclosureSEC source: 0001193125-26-346924 · ownership.xml · derivative · entry 1 Fuchs Charles S. · CIK 0001719576 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common Stock · 1,300,000 shares Expires 2036-08-09 F1 · shares: The reported option award was granted in connection with the Reporting Person's commencement of employment. Of the total option award, 21,480 shares were granted under the Issuer's 2021 Incentive Award Plan, with a portion intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code to the extent permitted by law. The remaining 1,278,520 shares were granted as a nonqualified stock option under the Issuer's 2026 Employment Inducement Incentive Award Plan. F2 · derivative.exercise_date: The reported option award vests as follows: 25% of the shares subject to the option will vest on the first anniversary of the date of grant, and the remaining 75% of the shares will vest in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. Read SEC document |
| July 24, 2026 Filed Jul 30, 2026 21:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001610717-26-000345 · form4.xml · derivative · entry 1 Fuchs Charles S. · CIK 0001719576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2036-07-23 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:06 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012298 · doc1.xml · derivative · entry 1 Fuchs Charles S. · CIK 0001719576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 18:03 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001567619-19-013824 · doc1.xml · derivative · entry 1 Fuchs Charles S. · CIK 0001719576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0000899243-18-016824 · doc4.xml · derivative · entry 1 Fuchs Charles S. · CIK 0001719576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 19:26 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $20.04 | $0.00 |
DisclosureSEC source: 0001140361-17-039390 · doc1.xml · derivative · entry 1 Fuchs Charles S. · CIK 0001719576 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from October 23, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.